A "normal" LDL can hide real heart risk, because LDL measures the weight of cholesterol, not the number of particles (ApoB) that actually drive plaque. We measure ApoB in every patient, check Lp(a) once, and look directly at the arteries with a CT angiogram instead of waiting for chest pain or a stress test. Heart disease builds over decades and is largely preventable, so we treat lifetime risk: lifestyle first, then specific medication to drive ApoB to physiologic lows. The goal is to keep your arteries clear for decades so a heart attack never gets its chance.
The Standard of Care Is Falling Short
Heart disease is still the number one killer because most clinics rely on outdated tests like LDL-C and only treat people after damage has already happened.
In my practice, I use advanced blood markers (ApoB, Lp(a)) and detailed heart imaging to find and slow plaque buildup decades before a heart attack is on the table.
Here is my honest, contrarian view. Heart disease should not be the leading cause of death. With the tools we have in 2026, it should sit much further down the list. The fact that it is still on top is a gap in how we use what we already know, not a gap in the science.
Here is what really keeps me up at night. For more than half of men, and even more women, the very first sign of heart disease is not chest pain. It is sudden cardiac death. Research keeps confirming this. The first time a person learns they have a problem should not be the day it kills them.
Every week in Philadelphia, I meet patients who left their previous doctor's office with a "normal" cholesterol report, then come to me years later asking why no one warned them. So I practice what I call Preventive Cardiology 3.0. I do not wait for an abnormal stress test. I work from a simple idea: atherosclerosis (plaque buildup inside the arteries) starts in childhood and shows up in adulthood. My goal is thorough, early prevention, so your risk of a heart attack stays as close to zero as biology allows.
Why Do People With "Normal" Cholesterol Still Have Heart Attacks?
LDL-C measures the weight of cholesterol in your blood, but ApoB counts the actual number of harmful particles. Particle number is what drives risk, so checking ApoB catches silent danger that a standard panel misses.
The standard lipid panel (Total Cholesterol, LDL-C, HDL-C, Triglycerides) was designed decades ago. It is a blunt tool.
- LDL-C (Low-Density Lipoprotein Cholesterol) measures the weight or concentration of cholesterol in your blood.
- ApoB (Apolipoprotein B) counts the number of particles that can crash into your artery wall and start plaque.
The Highway Analogy
Picture your artery as a highway.
- LDL-C tells you the total weight of the cargo inside the trucks.
- ApoB tells you the number of trucks on the road.
A traffic jam (atherosclerosis) is caused by the number of trucks, not the weight of what they carry. You can have "normal" LDL-C but a dangerously high ApoB count, a mismatch we call discordance. That is exactly why people with "normal" cholesterol still have heart attacks. We measure ApoB in every patient.
What Is Lipoprotein(a) and Why Does It Matter?
Lipoprotein(a), or Lp(a), is an inflammatory, genetically set particle that affects about 1 in 5 adults. Diet and exercise barely move it, so every adult should be screened for Lp(a) once to understand their true heart risk.
Roughly 20% of the population carries a genetic risk factor that most primary care doctors never test for. It is called Lipoprotein(a), often written as Lp(a) and read as "Lipoprotein(a)".
Lp(a) is a sticky, inflammatory cousin of LDL. It is locked in by your DNA, so kale and marathons have almost no effect on it. If your Lp(a) is high, your risk of a heart attack jumps no matter how good your lifestyle looks on paper.
Every adult should have Lp(a) checked at least once. If it is high, we get even more thorough about every other risk factor we can move. If you do not know your number, you are flying blind.
Can We Actually See Plaque Before a Heart Attack?
Yes. Modern AI-supported CT angiograms (CCTA) show the real state of your arteries, both the hard and the soft plaque, so we move from guessing risk to seeing it.
Standard medicine often waits for chest pain, then orders a stress test. A stress test only flags a blockage when an artery is more than 70% closed off. It says nothing about a 40% blockage that could rupture tomorrow.
I believe in looking directly at the arteries, not guessing and not waiting.
CT Angiogram (CCTA) vs. Calcium Score (CAC)
- CT Angiogram (CCTA): Uses a contrast dye to show all plaque, both calcified and soft, inside the artery walls. This is the gold standard for early detection. AI-powered analysis (such as Cleerly) measures plaque down to the millimeter.
- Calcium Score (CAC): Only measures calcified (hard) plaque, which is the "history" of old damage. A score of 0 does not mean you are safe, because soft, vulnerable plaque, the kind that drives most heart attacks, will not show up at all. We treat this test as incomplete for true risk assessment.
What Tools Do You Use to Lower Heart Risk?
Lowering cardiovascular risk takes a two-part plan: lifestyle and supplement strategies that calm inflammation, plus precise medications when lifestyle alone cannot drive ApoB low enough.
We do not rely on watchful waiting. We use every safe tool we have to slow or stop plaque progression.
| Focus | Functional Strategy (Optimization) | Traditional Strategy (Disease Eradication) |
|---|---|---|
| Plaque Stabilization | Aged Garlic Extract: Studies suggest it helps stabilize soft plaque and slow progression. | Statins (Rosuvastatin/Atorvastatin): A core tool for stabilizing plaque and lowering inflammation (hsCRP). |
| Lipid Lowering | Berberine / Red Yeast Rice: Natural compounds that act on similar pathways to statins. They are weaker, but useful for patients who cannot tolerate statins. | PCSK9 Inhibitors / Bempedoic Acid: Newer non-statin drugs that lower ApoB significantly without typical statin muscle aches. |
| Endothelial Health | Magnesium and Nitric Oxide support: Helps relax arteries and improve blood flow. | ACE Inhibitors / ARBs: Keep blood pressure under 120/80 to prevent mechanical damage to artery walls. |
| Metabolic Control | Fiber and Omega-3s: Bind bile acids and lower triglycerides. | GLP-1 Agonists / SGLT2 Inhibitors: Lower insulin resistance and reduce cardiovascular death risk. |
| Risk Assessment | hs-CRP / Homocysteine: Track ongoing inflammation. | ApoB / Lp(a): Track the actual particles that drive disease. |
Fishtown Medicine
A 90-minute conversation with Dr. Ash. A written plan you can actually follow.
What Is the Medicine 3.0 Strategy for Heart Disease?
The Medicine 3.0 approach treats heart disease based on lifetime risk, not a 10-year score. We use early, intentional lipid management, including non-statin options like PCSK9 inhibitors when needed, to keep arteries clear for decades.
If we find risk, we act. We do not wait for a heart attack to be the trigger for treatment.
A Word on Statins
There is a lot of fear about statins online. Statins are not the only tool, but they are often the right tool for people with genetically high ApoB. In Medicine 3.0 we have more options now. We use PCSK9 inhibitors (injectables), Ezetimibe, and Bempedoic Acid to bring ApoB down to physiologic lows (for example, under 60 mg/dL, or under 30 mg/dL for very high risk patients) without the muscle aches some people get on statins.
Guidance from the Clinic

Why I Push So Hard: I have read the post-mortem reports. The 45-year-old marathoner with a 70% LAD blockage no one caught because his LDL looked "normal." The executive who passed every stress test and then collapsed four months later. I have sat with families who asked, "How did we miss this?" That experience shapes my urgency. I look for it now so you never have to ask that question.
"Dr. Ash, my dad had a heart attack at 50. Am I doomed?"
Here is how I think about it. Genetics deal the cards, but lifestyle plays the hand. In your case, we have a lot of room to play that hand differently.
Heart disease is unique because it is slow. It takes decades to build a real blockage. That gives us a long runway. If we keep your ApoB low, your blood pressure optimized, and your insulin sensitivity high for 20 years, it becomes very hard, biologically, to grow enough plaque to kill you.
I do not just "manage" heart disease. I aim to remove it from your future.
Actionable Steps in Philly
Do not wait for your primary care doctor to offer these tests. Ask for ApoB and Lp(a), and schedule a heart CT angiogram if you are over 40. Data is the antidote to anxiety.
- Get an ApoB Test: Do not settle for LDL alone. Ask for ApoB.
- Check Lp(a) Once: If you have a family history of heart disease, do this soon.
- Know Your Plaque: If you are a man over 40 or a woman over 50, a CT angiogram (CCTA) shows both calcified and soft plaque, catching what a calcium score alone would miss. Out-of-pocket cost is around $300 to $500, and insurance often covers it when there is a clinical reason.
Supplements for Cardiovascular Support
Beyond medications, these evidence-backed supplements can support heart health:
- CoQ10: Helps mitochondria make energy, particularly for people on a statin.
- NAC (N-Acetyl Cysteine): Supports glutathione (an antioxidant your body makes) and lowers oxidative stress.
- Omega-3 Fatty Acids: Lower triglycerides and reduce inflammation.
At Fishtown Medicine, we handle the prescriptions, the scheduling with local imaging centers (like Penn or Jefferson), and the careful read of every result.
Protect your engine.
Book Your Warm Invitation Call Here
Key Takeaways
- LDL-C measures cholesterol weight, while ApoB counts the particles that actually drive plaque, so we measure ApoB in every patient.
- Lp(a) is a genetic risk factor affecting about 1 in 5 adults and is worth checking once in every adult.
- A CT angiogram shows both hard and soft plaque; a calcium score of 0 does not rule out the soft plaque that causes most heart attacks.
- Heart disease builds over decades, so we treat lifetime risk and aim for ApoB well under 60 mg/dL when risk is high.
- Genetics deal the cards, but lifestyle plays the hand, and starting early makes a fatal heart attack very hard to reach.
Scientific References
- Strong JP, et al. Prevalence and extent of atherosclerosis in adolescents and young adults. JAMA. 1999;281(8):727-735. The landmark PDAY study establishing that heart disease begins in childhood.
- Sniderman AD, et al. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiol. 2019;4(12):1287-1295. Demonstrates why ApoB is a superior predictor of risk compared to LDL-C.
- Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. J Am Coll Cardiol. 2017;69(6):692-711. Highlights that ~20% of the population has elevated Lp(a).
- The SCOT-HEART Investigators. Coronary CT Angiography and 5-Year Risk of Myocardial Infarction. N Engl J Med. 2018;379:924-933. Validates the use of CCTA for clarifying risk and reducing heart attacks.
- Mach F, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41(1):111-188. Establishes intensive ApoB targets (< 65 mg/dL) for high-risk prevention.
- Zheng ZJ, et al. Sudden Cardiac Death in the United States, 1989 to 1998. Circulation. 2001. Confirms that >50% of CHD deaths occur out of hospital/suddenly.
- Fox CS, et al. Parental Cardiovascular Disease as a Risk Factor for Cardiovascular Disease in Middle-Aged Adults (The Framingham Heart Study). Circulation. 2004. Highlighting the often silent, sudden nature of first events.

Fishtown Medicine | Articles
Frequently Asked Questions
Common Questions
Deep-Dive Questions
Ready when you are
Dr. Ash reads every intake himself, and answers questions personally - usually within a few hours.




